Mary Tagliaferri - 12 Mar 2024 Form 4 Insider Report for Y-mAbs Therapeutics, Inc. (YMAB)

Role
Director
Signature
/s/ John LaRocca, Attorney-in-Fact
Issuer symbol
YMAB
Transactions as of
12 Mar 2024
Net transactions value
$0
Form type
4
Filing time
14 Mar 2024, 17:01:25 UTC
Previous filing
08 Mar 2024
Next filing
13 Jun 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction YMAB Common Stock Award $0 +4,660 $0.000000 4,660 12 Mar 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction YMAB Stock Option (right to buy) Award $0 +27,900 $0.000000 27,900 12 Mar 2024 Common Stock 27,900 $16.09 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents 4,660 restricted stock units ("RSUs") granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc. Each RSU represents a contingent right to receive one share of Common Stock on the vesting date of the RSUs. The RSUs vest in equal quarterly installments over a three-year period measured from three months following March 12, 2024, subject to the Reporting Person's continued service through each applicable vesting date.
F2 Stock options granted to the Reporting Person as a non-employee director pursuant to the 2018 Equity Incentive Plan of Y-mAbs Therapeutics, Inc.
F3 The stock option shall vest and become exercisable in equal monthly installments over a three-year period measured from one month following March 12, 2024, subject to the Reporting Person's continued service through each applicable vesting date.